UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

Spironolactone

In Vitro Substrates

No substrate information.

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Substrate used	Cell System	Reference
SLC22A1	OCT1	Spironolactone	1.2	1-methyl-4-phenylpyridinium (MPP+)	MDCK-OCT1	Grube, 2011
SLC22A1	OCT1	Spironolactone	3.08	4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+)	HEK293-OCT1	Ahlin, 2010
SLC47A1	MATE1	Spironolactone	18.6	4-(4-dimethylamino)styryl-N-methylpyridinium (ASP+)	HEK293-MATE1	Wittwer, 2013
ABCB1	MDR1, P-gp	Spironolactone	23.6	Daunorubicin	NIH-G185 cells	Wang, 2001
OSTalpha	OSTA	Spironolactone	>200	Estrone sulfate	OSTalpha-OSTbeta expressing oocytes	Seward, 2003
OSTbeta	OSTB	Spironolactone	>200	Estrone sulfate	OSTalpha-OSTbeta expressing oocytes	Seward, 2003
SLC22A5	OCTN2	Spironolactone	36	L-carnitine	MDCKII-hOCTN2	Grube, 2011
SLC22A2	OCT2	Spironolactone	1.29	Metformin	HEK293-OCT2	Hacker, 2015
SLC22A4	OCTN1	Spironolactone	125	Tetraethylammonium	MDCKII-hOCTN1	Grube, 2011

No drug-drug interaction information.